PULSE BIOSCIENCES, INC. (PLSE): Results of Operations and Financial Condition
PULSE BIOSCIENCES, INC. (PLSE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_964658.htm PRESS RELEASE ISSUED BY PULSE BIOSCIENCES, INC. DATED AUGUST 6, 2026 - BUSINESS UPDATES AND FINANCIAL RESULTS ex_964658.htm Exhibit 99.1 Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results HAYWARD, California [Business Wire
How this was made
The 30-second read
Why it matters
Key disclosed items include cash raised under an ATM, updated enrollment status and protocol amendment for the NANOPULSE-AF pivotal trial, and progress toward CE Mark submissions. These details affect near-term financing expectations and the perceived probability of hitting clinical and regulatory milestones.
Market read
Traders get fresh, decision-relevant updates on pivotal trial enrollment pace, protocol qualification expansion, and cash runway via ATM financing, alongside updated loss and revenue figures.
What to watch
Cash balance rose via ATM, but the company also increased operating investment and remains loss-making, so future dilution risk could cap rallies even with clinical progress.
Background
This is an SEC 8-K with an attached press release covering Q2 2026 business updates and financial results for Pulse Biosciences.
Ticker impact
Pulse Biosciences reported Q2 2026 results and said NANOPULSE-AF enrollment is past 82 evaluable patients, targeting early Q4 completion.
Near-term bias modestly positive, with volatility tied to ongoing enrollment pace and future financing needs.
The filing discloses concrete enrollment metrics, protocol amendment expanding qualifying AAD classes, and cash raised under an ATM, all of which can move biotech risk perception. However, it also reiterates ongoing GAAP and non-GAAP net losses, limiting upside conviction.
Market effects
Reinforces investor focus on procedural adoption and regulatory timelines for cardiac ablation platforms using pulsed field ablation.
Limited direct regional impact; primarily US clinical execution with CE Mark pathway.
CE Mark submission and potential mid-2027 approval timing keep European regulatory milestones in traders’ radar.
Counterpoint
Enrollment momentum may not translate into faster regulatory approval; protocol changes and expanded targets can also increase variability in outcomes.
Key entities
- issuerPulse Biosciences, Inc.
Nasdaq-listed company developing nanosecond pulsed field ablation systems; subject of the 8-K and press release.
- clinical_programNANOPULSE-AF
U.S. IDE pivotal study for the nPulse Cardiac Catheter System; enrollment and protocol qualification criteria were updated.
- partnerClayman Thyroid Center
Named partnership site for demonstrating Vybrance system therapy viability for benign thyroid nodules.
- collaboratorMD Anderson Cancer Center
Named collaboration for first-in-human feasibility in papillary thyroid microcarcinoma.